Lung Cancer Screening Software Market Analysis Report 2025-2030: Emerging Opportunities For Early Detection, Risk Assessment, And Treatment Monitoring

(MENAFN- GlobeNewsWire - Nasdaq) The market is poised for growth due to rising demand for early detection technologies, integration with AI & imaging advancements, and evolving reimbursement models. Opportunities stem from regional adoption disparities, technology partnerships, and the shift towards cloud-based, interoperable solutions.

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "Lung Cancer Screening Software Market by Software Type, Functionality, Lung Cancer Type, Application, End User, Deployment Mode - Global Forecast 2025-2030" has been added to ResearchAndMarkets's offering.

The Lung Cancer Screening Software Market is experiencing robust growth, expanding from USD 2.82 billion in 2024 to USD 3 billion in 2025, and projected to reach USD 4.16 billion by 2030 at a CAGR of 6.70%. Demand is driven by the need for innovative screening solutions capable of enhancing early detection and improving patient outcomes through advanced imaging technologies and artificial intelligence.

This comprehensive report provides essential insights into the critical need and emerging opportunities in the lung cancer screening software sector to guide strategic planning and decision-making.

Lung cancer remains a leading cause of cancer-related mortality worldwide, necessitating sophisticated screening software solutions. The evolution of imaging technologies and AI algorithms are making these platforms pivotal in interpreting complex radiological data, helping clinicians identify suspicious nodules with greater accuracy. This trend is encouraged by shifting clinical guidelines and an aging population at higher risk, placing significant emphasis on population health management. Regulatory bodies fast-tracking approvals for software-as-a-medical-device solutions further bolster market growth.

Technological Disruptions and Industry Shifts

Breakthroughs in machine learning have catalyzed the shift from standalone image viewers to comprehensive software platforms. These platforms integrate advanced analytics with electronic health records, providing actionable intelligence in real time, reducing diagnostic time, and enabling precise treatment planning. Concurrently, evolving reimbursement frameworks reward value-based care, encouraging the adoption of technology that demonstrates cost savings through early intervention. This creates a strategic advantage for decision-makers seeking to mitigate risks and identify new opportunities in the healthcare landscape.

Tariffs Impact on Market Dynamics

In 2025, tariffs on medical device components and imported hardware introduced cost challenges for software vendors. These changes prompted a reevaluation of supply chain strategies, encouraging some companies to source components domestically. Tariffs have also spurred local innovation, leading to the development of hardware-agnostic software that interfaces with various imaging devices, reducing dependency and allowing incremental upgrades. Such adaptation exemplifies the agility required to sustain growth in a dynamic trade environment.

Key Takeaways from This Report

• Markets are shifting towards integrated software platforms offering analytics, coordination, and workflow tools to improve precision oncology.
• The U.S. tariff scenario emphasizes the need for flexible software design and local manufacturing to protect against cost increases.
• Decisions hinging on software type and deployment mode - from cloud-based solutions to comprehensive suites - reflect varied institutional priorities and digital maturity.
• Regional disparities highlight specific growth drivers, with the Americas leading in adoption, while the Asia-Pacific region boosts aggressive digital health initiatives.
• Strategic partnerships and alliances are key in enhancing technology portfolios and ensuring seamless market entry.

Regional Disparities and Growth Drivers

The report reveals regional disparities, with the Americas at the forefront due to substantial investments in healthcare IT and early AI diagnostics adoption. Conversely, Europe's regulatory landscape and the Middle East & Africa's telehealth infrastructure present diverse opportunities. Asia-Pacific is notable for integrating AI-enabled tools in high-volume imaging workflows, indicative of how market entry strategies must adapt to regional nuances.

Competitive Landscape Strategies

Market leaders are enhancing competitive positions through acquisitions, partnerships, and technological alliances. Established companies enrich imaging platforms with AI-based analytics, while pure-play vendors focus on swift, innovative development cycles. Such strategic moves allow these vendors to gain a competitive advantage and meet the nuanced demands of healthcare organizations.

Strategic Imperatives

Industry leaders are called to develop open, scalable platforms that facilitate integration with third-party systems, reducing obsolescence risks and fostering long-term relationships. Engaging with regulatory bodies and investing in clinical studies are critical for aligning with data security requirements and ensuring reimbursement model advantages. By prioritizing open platforms and solid customer support, companies can reinforce their market leadership for the future.

Key Attributes

Report Attribute	Details
No. of Pages	196
Forecast Period	2025-2030
Estimated Market Value (USD) in 2025	$3 Billion
Forecasted Market Value (USD) by 2030	$4.16 Billion
Compound Annual Growth Rate	6.7%
Regions Covered	Global

Key Topics Covered
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing integration of AI-driven risk stratification algorithms in lung cancer screening workflows
5.2. Rising adoption of ultra-low-dose CT protocols to minimize radiation exposure in lung screening
5.3. Expansion of telehealth-based lung cancer screening programs in underserved rural areas
5.4. Evolution of deep learning models for automated nodule detection and malignancy classification
5.5. Growing implementation of cloud-based data analytics platforms for large-scale screening studies
5.6. Surge in multiomics biomarker incorporation for personalized lung cancer screening assessments
5.7. Advancements in patient engagement tools leveraging mobile applications for screening adherence
6. Market Insights
6.1. Porter's Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Lung Cancer Screening Software Market, by Software Type
8.1. Introduction
8.2. Integrated Solutions
8.3. Standalone
9. Lung Cancer Screening Software Market, by Functionality
9.1. Introduction
9.2. Data Collection and Reporting
9.3. Lung Cancer Screening Patient Management Software
9.4. Lung Cancer Screening Radiology Solution
9.5. Nodule Management Software
9.6. Patient Coordination and Workflow
10. Lung Cancer Screening Software Market, by Lung Cancer Type
10.1. Introduction
10.2. Non-Small Cell Lung Cancer (NSCLC)
10.3. Small Cell Lung Cancer (SCLC)
11. Lung Cancer Screening Software Market, by Application
11.1. Introduction
11.2. Early Detection
11.3. Risk Assessment
11.4. Treatment Monitoring
12. Lung Cancer Screening Software Market, by End User
12.1. Introduction
12.2. Cancer Centers
12.3. Diagnostic Imaging Centers
12.4. Hospitals
12.5. Research Institutions
13. Lung Cancer Screening Software Market, by Deployment Mode
13.1. Introduction
13.2. Cloud-based
13.3. On-premise
14. Americas Lung Cancer Screening Software Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Lung Cancer Screening Software Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Lung Cancer Screening Software Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
The companies profiled in this Lung Cancer Screening Software Market report include:

• Aidoc Medical, Ltd.
• Behold Limited
• Canon Medical Systems Corporation
• ContextVision AB
• DeepHealth, Inc. by RadNet, Inc.
• Enlitic, Inc.
• Fujifilm Holdings Corporation
• General Electric Company
• Hologic, Inc.
• iCAD, Inc.
• Infervision Medical Technology Co., Ltd.
• Koninklijke Philips N.V.
• Lunit Inc.
• Optellum Ltd.
• Proscia Inc.
• Qure Technologies Private Limited
• RadLogics, Inc.
• Siemens Healthineers AG
• Inc.
• Zebra Medical Vision Ltd.
• Microsoft Corporation
• Oracle Corporation
• Google LLC by Alphabet Inc.
• NVIDIA Corporation

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Lung Cancer Screening Software Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08092025004107003653ID1110032055